Abivax's CEO Marc de Garidel stated that the company is not in a hurry to pursue partnerships or sales, preferring to wait for the results of a crucial June trial to negotiate better terms.
Takeover Rumors and Market Speculation
- The French biotech firm has faced intense takeover speculation for months, driving significant stock volatility.
- Shares rose nearly 1,700% in 2025, reflecting investor bets on a potential acquisition by pharma giants.
- Analysts widely view Abivax as a prime target due to its promising drug pipeline.
Key Trial Data and Regulatory Pathway
- A second late-stage trial evaluating obefazimod's long-term maintenance effect is scheduled to report results in late Q2 2025.
- Positive data would lead to a U.S. FDA approval application in Q4 2025.
- Obefazimod is positioned as a potentially best-in-class treatment for ulcerative colitis and is also in trials for Crohn's disease, targeting the large irritable bowel syndrome market.
CEO's Strategic Stance
- De Garidel emphasized that waiting for the maintenance trial results will yield more favorable terms for partnerships or deals.
- "Why hurry?" he remarked, noting the readout is just three months away and confidence in positive outcomes.
- The upcoming data is considered a major inflection point, closely monitored by investors and potential buyers.
Financial Position and Future Plans
- As of end-2025, Abivax reported 530 million euros ($613 million) in cash, sufficient to operate through late 2027.
- Post-trial, the company plans to raise capital through a mix of equity and debt financing to achieve profitability.
- Previously, in July, Abivax raised nearly $750 million after a prior trial success boosted shares by 510% in one day.